Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Toremifene is a selective estrogen receptor modulator or SERM. Some time ago, its developer (GTx, Inc.) initiated a Phase III clinical trial to investigate whether toremifene at a dose of 80 mg/day lowered risk for new vertebral fractures in prostate cancer patients being treated with androgen deprivation therapy (ADT).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: benefit, fracture, Prevention, risk, toremifene | 2 Comments »
According to a media release from GTx and other reports, the US Food and Drug Administration (FDA) has requested additional information about the effectiveness and safety of toremifene 80 mg before they will be willing to approve a New Drug Application (NDA) for this drug as a treatment to reduce fractures in men with prostate [...]
Filed under: Drugs in development, Uncategorized | Tagged: toremifene | Leave a Comment »
Two important papers presented this afternoon addressed data on the use of toremifene and denosumab on the bones of men receiving treatment with androgen deprivation therapy (ADT).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation therapy, bone mineral denisty, denosumab, fractures, toremifene | Leave a Comment »
Today’s news covers: The ongoing trial of toremifene 20 mg in prevention of prostate cancer Interleukin-6 in the development of prostate cancer Preservation of the fascia and recovery of erectile function post-surgery The use of urethral wall stents and delayed artificial urinary sphincters to treat men with severe, recurrent bladder neck contracture and incontinence after [...]
Filed under: Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: contracture, erectile function, fascia, incontinence, interleukin-6, PIN, preservation, prostatic intraepithelial neoplasia, sphincter, stent, toremifene | 1 Comment »
Today’s important news reports address: 5- and 7-year survival data following iodine-125 permanent implant brachytherapy Risks associated with low levels of lymphocyte apoptosis in patients receiving radiation therapy Stiffening of the large arteries in men receiving antiandrogen therapy The status of the toremifene and denosumab applications for approval for marketing in the USA
Filed under: Drugs in development, Management, Treatment | Tagged: antiandrogen, apoptosis, approval, arteries, brachytherapy, denosumab, iodine-125, long-term, lymphocyte, radiation therapy, stiffening, survival, toremifene, toxicity | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site